Rise Nano's Spectraguard classified as exempt device

Executive Summary

• Rise Nano Optics Ltd. has received FDA Class I exempt medical device classification for its proprietary Spectraguard nano-optic lens technology, validating its safety profile and intended use for eye protection.
• The FDA has accepted the company's stated intended use claim, confirming the lenses filter 100% of ultraviolet light and up to 90% of wavelengths between 400 and 600 nanometres (including blue light) while preserving visual clarity.
• This regulatory milestone enables the company to import products and fully launch commercialization efforts in the United States, targeting a significant portion of the $160-billion global eyewear market.

Key Details

• Regulatory Status: FDA Class I exempt medical device classification; FDA registration completed.
• Product Specifications: Spectraguard nano-optic lens technology filters 100% of UV light and up to 90% of wavelengths between 400-600 nm (including blue light).
• Performance Claims: Preserves natural visual clarity and color perception; designed to reduce glare, digital eye strain, and long-term vision stress.
• Testing & IP: Follows successful completion of biocompatibility testing; supported by multiple patents protecting nano-material formulations, lens architecture, and scalable manufacturing processes.
• Commercial Strategy: Executing a multichannel strategy targeting eye care professionals, lens manufacturers, optical labs, eyewear brands, and direct-to-consumer platforms.
• Market Context: U.S. represents a major revenue opportunity within the $160-billion (U.S.) global eyewear market; over 90% of U.S. adults use some form of eyewear.
• Management: Recent appointment of Erik Ritchie as chief commercial officer to support U.S. launch.

Notable Quotes

• "This regulatory milestone represents an important derisking event as we accelerate our commercialization strategy... FDA registration and Class I classification validate the safety profile and intended use of our Spectraguard technology and allow us to continue executing our multipronged commercialization strategy across North America." — Inas Said, Founder and CEO